Gabizon AA - Search Results

1

Pharmacokinetics of mitomycin-c lipidic prodrug entrapped in liposomes and clinical correlations in metastatic colorectal cancer patients.

Gabizon AA, Tahover E, Golan T, Geva R, Perets R, Amitay Y, Shmeeda H, Ohana P. Gabizon AA, et al. Invest New Drugs. 2020 Oct;38(5):1411-1420. doi: 10.1007/s10637-020-00897-3. Epub 2020 Jan 18. Invest New Drugs. 2020. PMID: 31955309 Clinical Trial.

2

Polyethylene glycol-coated (pegylated) liposomal doxorubicin. Rationale for use in solid tumours.

Gabizon A, Martin F. Gabizon A, et al. Drugs. 1997;54 Suppl 4:15-21. doi: 10.2165/00003495-199700544-00005. Drugs. 1997. PMID: 9361957 Review.

3

Selective delivery of doxorubicin to patients with breast carcinoma metastases by stealth liposomes.

Symon Z, Peyser A, Tzemach D, Lyass O, Sucher E, Shezen E, Gabizon A. Symon Z, et al. Cancer. 1999 Jul 1;86(1):72-8. Cancer. 1999. PMID: 10391566

4

Pharmacological studies of cisplatin encapsulated in long-circulating liposomes in mouse tumor models.

Bandak S, Goren D, Horowitz A, Tzemach D, Gabizon A. Bandak S, et al. Anticancer Drugs. 1999 Nov;10(10):911-20. doi: 10.1097/00001813-199911000-00007. Anticancer Drugs. 1999. PMID: 10630359

5

Doxil (Caelyx): an exploratory study with pharmacokinetics in patients with hormone-refractory prostate cancer.

Hubert A, Lyass O, Pode D, Gabizon A. Hubert A, et al. Anticancer Drugs. 2000 Feb;11(2):123-7. doi: 10.1097/00001813-200002000-00009. Anticancer Drugs. 2000. PMID: 10789595 Clinical Trial.

6

Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma.

Lyass O, Uziely B, Ben-Yosef R, Tzemach D, Heshing NI, Lotem M, Brufman G, Gabizon A. Lyass O, et al. Cancer. 2000 Sep 1;89(5):1037-47. doi: 10.1002/1097-0142(20000901)89:5<1037::aid-cncr13>3.0.co;2-z. Cancer. 2000. PMID: 10964334 Clinical Trial.

7

Reduced toxicity and superior therapeutic activity of a mitomycin C lipid-based prodrug incorporated in pegylated liposomes.

Gabizon AA, Tzemach D, Horowitz AT, Shmeeda H, Yeh J, Zalipsky S. Gabizon AA, et al. Clin Cancer Res. 2006 Mar 15;12(6):1913-20. doi: 10.1158/1078-0432.CCR-05-1547. Clin Cancer Res. 2006. PMID: 16551877

8

Pros and cons of the liposome platform in cancer drug targeting.

Gabizon AA, Shmeeda H, Zalipsky S. Gabizon AA, et al. J Liposome Res. 2006;16(3):175-83. doi: 10.1080/08982100600848769. J Liposome Res. 2006. PMID: 16952872 Review.

9

Folate-mediated tumor cell uptake of quantum dots entrapped in lipid nanoparticles.

Schroeder JE, Shweky I, Shmeeda H, Banin U, Gabizon A. Schroeder JE, et al. J Control Release. 2007 Dec 4;124(1-2):28-34. doi: 10.1016/j.jconrel.2007.08.028. Epub 2007 Aug 30. J Control Release. 2007. PMID: 17928088

10

Emerging delivery systems to reduce doxorubicin cardiotoxicity and improve therapeutic index: focus on liposomes.

Tahover E, Patil YP, Gabizon AA. Tahover E, et al. Among authors: gabizon aa. Anticancer Drugs. 2015 Mar;26(3):241-58. doi: 10.1097/CAD.0000000000000182. Anticancer Drugs. 2015. PMID: 25415656 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

83 results

Search Page

Filters